Related Experiment Video

Updated: Jul 6, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma

Jessica Dal Col1, Paola Zancai, Liliana Terrin

  • 1Cancer Bio-Immunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico (CRO), Istituto di Ricovero e Cura a Caratiere Scientifico (IRCCS) National Cancer Institute, Aviano, Italy.

Blood
|March 15, 2008
PubMed

Insights

Targeting the Akt pathway, not mTOR, shows promise for mantle cell lymphoma (MCL) therapy. Akt inhibition halts MCL cell growth and survival by affecting key cell cycle regulators and inducing apoptosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Mantle cell lymphoma (MCL) is driven by signaling pathways crucial for cell growth and survival.
  • Constitutive Akt activation, linked to inactive PTEN, is observed in MCL.
  • Understanding these pathways is key to developing novel MCL therapies.

Purpose of the Study:

  • To functionally characterize the PI3-K/Akt/mTOR signaling pathway in MCL.
  • To evaluate the therapeutic potential of inhibiting Akt and mTOR in MCL.
  • To elucidate the downstream mechanisms of Akt and mTOR inhibition in MCL.

Main Methods:

  • Inhibition of Phosphatidyl-inositol-3 kinase (PI3-K)/Akt and mammalian target of rapamycin (mTOR) pathways.
  • Assessment of cell growth in primary MCL cultures and cell lines.
  • Analysis of protein expression, including p27(Kip1), p45(Skp2), Cks1, cyclin D1, and GSK-3.
  • Evaluation of apoptosis and telomerase activity.

Main Results:

  • PI3-K/Akt or mTOR inhibition reduced MCL cell growth and antagonized CD40/IL-4 effects.
  • Inhibition led to p27(Kip1) nuclear accumulation via down-regulation of p45(Skp2) and Cks1.
  • Akt inhibition promoted proteasome-dependent degradation of cyclin D1 via GSK-3.
  • mTOR inhibition's effect on cyclin D1 depended on GSK-3's regulation by mTOR.
  • Akt inhibitors induced apoptosis and reduced telomerase activity, unlike rapamycin.

Conclusions:

  • Akt and mTOR signaling have distinct roles in MCL pathogenesis.
  • Targeting the Akt pathway may offer more effective therapeutic benefits than targeting mTOR in MCL.
  • Differential regulation of GSK-3 by mTOR suggests variable responses to mTOR inhibitors in MCL subsets.

More Related Videos

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...